Pemigatinib
MCE 国际站:Pemigatinib
CAS:1513857-77-6
品牌:MedChemExpress (MCE)
存储条件:Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
生物活性: Pemigatinib (INCB054828) 是一种具有口服活性的选择性 FGFR 抑制剂,IC50 分别为 0.4 nM、0.5 nM、1.2 nM、30 nM,用于分别为 FGFR1、FGFR2、FGFR3、FGFR4。 Pemigatinib 具有潜在的胆管癌[1][2]。 体外:这一假设得到了体外细胞研究的证实,在这些研究中,表达 FGFR2-CLIP1 融合的细胞对 Pemigatinib 敏感(INCB054828;IC50</ sub> 值为 10.16 nM),而添加 N549H 突变的细胞对 Pemigatinib 具有耐药性(IC50 值为 1527.57 nM)[3]。
体外:这一假设得到体外细胞研究的证实,其中表达 FGFR2-CLIP1 融合的细胞对 Pemigatinib 敏感(INCB054828;IC50 值为 10.16 nM),而添加 N549H 突变的细胞对 Pemigatinib 具有耐药性(IC50 值为 1527.57 nM)[3]。
热销产品:Ceftazidime | DTNB | XMD8-92 | 7-Aminoactinomycin D | Bergamottin | Streptomycin (sulfate) | Methyltetrazine-acid | PT2399 | ML339 | Talazoparib tosylate
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:FGFR
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
参考文献:
[1]. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.[2]. Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.[3]. Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).